Pregnancy loss

Т. Н. Тутченко

Abstract


It was found that immunologic factors are the cause of 50% happening of idiopathic recurrent miscarriage. It is proved that progesterone plays an important role in the establishment of adequate immune environment in the early stages of pregnancy. The results of the study described in this article, as well as a number of other studies suggest that the use of such progesterone isomers as dydrogesterone in women with idiopathic recurrent pregnancy loss improves pregnancy outcomes - reduces the incidence of recurrent abortions, extends gestational age and reduces the risk of obstetric complications


Keywords


recurrent pregnancy loss; immunological causes of miscarriage; progesterone; dydrogesterone

References


Renzo, J.C.P., Pietta, V.O., et al. “Modern aspects of miscarriage.” Health of Ukraine, 7(2009): 67–68.

Sidelnikova, V.M., Sukhikh, G.T. Pregnancy loss. Guidelines for Clinicians. M. MIA (2010): 536 p.

Pisareva, S.P. “Differentiated approach to the use of drugs with progestin action in pregnancy loss.” Doctors Country, 2012, [http://medstrana.com/articles/4112/], last accessed 24 Apr 2015.

Shormila, R., Knapp, L.A. “Human reproductive failure I: immunological factors.” Hum Reprod Update, 7(2000): 113–134.

Zhuk, S.I., Kalinka, Y., Sidelnikova, V.M., et al. “Miscarriage: a new look at an old problem.” Medical Aspects of Women's Health, 2 (7) (2007).

P iccinni, M.P., Giudizi, M.G., Biagiotti, R., Beloni, L., Giannarini, L., Sampognaro, S., et al. “Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established T cell clones.” J Immunol, 155(1995): 128–133.

C hoi, B.C., Polgar, K., Xiao, L., Hill, J.A. “Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss.” Hum Reprod, 15(2000) (Suppl 1): 46–59.

D aya, S., Ward, S., Burrows, E. “Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion.” Am J Obstet Gynecol, 158(1988): 225–232.

Kumar, A., Begum, N., Prasad, S., Aggarwal, S. “Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial.” Fertility and Sterility, 5(102) (2014): 1357–1363.

N ybo Andersen, A.-M., Wohlfahrt, J., Christens, P., Olsen, J., Melbye, M. “Maternal age and fetal loss: population based register linkage study.” Brit Med J, 320(2000): 1708–1712.

A merican College of Obstetricians and Gynecologists (ACO G). Early pregnancy loss. ACO G Tech Bull No. 212. Washington, DC (1995).

Schindler, A.E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J.R., Schweppe, K.W. “Classification and pharmacology of progestins.” Maturitas, 46(2003) (Suppl 1): 7–16.

Benifla, J.L., Dumont, M., Levardon, M., Foucher, E., Cadiot, G., Crenn-Hebert, C., et al. “Effects of micronized natural progesterone on the liver during the third trimester of pregnancy.” Contracept Fertil Sex, 25(1997): 165–169.

M ackenzie, R., Walker, M., Armson, A., Hannah, M.E. “Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and metaanalysis of randomized controlled trials.” Am J Obstet Gynecol, 194(2006): 1234–1242.

O mar, M.H., Mashita, M.K., Lim, P.S., Jamil, M.A. “Dydrogesterone in threatened abortion: pregnancy outcome.” J Steroid Biochem Molec Biol, 97(2005): 421–425.

Kalinka, Y., Radwan, M. “The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion.” Am J Reprod Immunol, 55(2006): 115–121.

C arp, H. “A systematic review of dydrogesterone for the treatment of threatened miscarriage.” Gynecol Endocrinol, 28(2012): 983–990.


GOST Style Citations


1. Рензо, Ж.-К. Современные аспекты невынашивания беременности / Ж.-К. Рензо, П. Пиетта и др. // Здоровье Украины. — 2009. — № 7. — С. 67–68.

2. Сидельникова, В.М., Сухих, Г.Т. Невынашивание беременности. Руководство для практикующих врачей. — М.: МИА, 2010. — 536 с.

3. Писарева, С.П. Дифференцированный подход к применению препаратов гестагенного действия при невынашивании беременности / С.П. Писарева // Страна врачей, 2012, [http://medstrana.com/articles/4112/], последнее обращение 24.04.2015.

4. Shormila, R., Knapp, L.A. “Human reproductive failure I: immunological factors.” Hum Reprod Update, 7(2000): 113–134.

5. Жук, С.И. Невынашивание беременности: новый взгляд на старую проблему / С.И. Жук, Я. Калинка, В.М. Сидельникова и др. // Медицинские аспекты здоровья женщины. — 2007. — № 2 (7).

6. P iccinni, M.P., Giudizi, M.G., Biagiotti, R., Beloni, L., Giannarini, L., Sampognaro, S., et al. “Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established T cell clones.” J Immunol, 155(1995): 128–133.

7. C hoi, B.C., Polgar, K., Xiao, L., Hill, J.A. “Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss.” Hum Reprod, 15(2000) (Suppl 1): 46–59.

8. D aya, S., Ward, S., Burrows, E. “Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion.” Am J Obstet Gynecol, 158(1988): 225–232.

9. Kumar, A., Begum, N., Prasad, S., Aggarwal, S. “Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial.” Fertility and Sterility, 5(102) (2014): 1357–1363.

10. N ybo Andersen, A.-M., Wohlfahrt, J., Christens, P., Olsen, J., Melbye, M. “Maternal age and fetal loss: population based register linkage study.” Brit Med J, 320(2000): 1708–1712.

11. A merican College of Obstetricians and Gynecologists (ACO G). Early pregnancy loss. ACO G Tech Bull No. 212. Washington, DC (1995).

12. Schindler, A.E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J.R., Schweppe, K.W. “Classification and pharmacology of progestins.” Maturitas, 46(2003) (Suppl 1): 7–16.

13. Benifla, J.L., Dumont, M., Levardon, M., Foucher, E., Cadiot, G., Crenn-Hebert, C., et al. “Effects of micronized natural progesterone on the liver during the third trimester of pregnancy.” Contracept Fertil Sex, 25(1997): 165–169.

14. M ackenzie, R., Walker, M., Armson, A., Hannah, M.E. “Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and metaanalysis of randomized controlled trials.” Am J Obstet Gynecol, 194(2006): 1234–1242.

15. O mar, M.H., Mashita, M.K., Lim, P.S., Jamil, M.A. “Dydrogesterone in threatened abortion: pregnancy outcome.” J Steroid Biochem Molec Biol, 97(2005): 421–425.

16. Kalinka, Y., Radwan, M. “The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion.” Am J Reprod Immunol, 55(2006): 115–121.

17. C arp, H. “A systematic review of dydrogesterone for the treatment of threatened miscarriage.” Gynecol Endocrinol, 28(2012): 983–990.





DOI: http://dx.doi.org/10.18370/2309-4117.2015.22.62-64

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)